Introduction & Objective: To analyze the influence of timing and type of predinner rapid insulin and basal insulin on the nocturnal glucose profile.
Methods: Real-world, retrospective study in T1D people using multiple daily injections. Ten hours from dinner of paired continuous glucose monitoring data and insulin injections automatically tracked with the connected cap Insulclock® were analyzed. Meal events were identified using the ROC detection methodology. Glucometrics were evaluated according to insulin injection time around the dinner and short- and long-acting analog types.
Results: Nocturnal profiles (n=775, 49 subjects) were analyzed. Higher nocturnal glucose AUC over 180 mg/dL was observed in delayed injections (mean <u>+</u>SD; mg/dL x h): -45-15 min (n=136; 17.5%), 175.96 ±271.0; -15-0 min (n= 231; 29.8%), 164.0 ±237.1; 0+45 min (n= 408; 52.6%), 203.6 ±260.9, (p 0.049). Ultrarapid (FiAsp®) vs rapid insulin analogs use was associated with fewer events of glucose <70 mg/dl (7.1 vs 13.6; p 0.0051) and TBR70 (1.67 vs 4.58%; p 0.0036). Events of glucose <70 mg/dL and TBR70 adjusted by baseline glucose were similar by basal insulin type (glargine U300 vs degludec).
Conclusion: The timing and type of dinner prandial insulin affect the entire nocturnal glucose profile.
F. Gomez-Peralta: Advisory Panel; Abbott. Speaker's Bureau; Abbott. Advisory Panel; Eli Lilly and Company. Speaker's Bureau; Eli Lilly and Company. Advisory Panel; Insulcloud S.L. Speaker's Bureau; Medtronic. Advisory Panel; Novo Nordisk. Speaker's Bureau; Novo Nordisk. Advisory Panel; Sanofi. X. Valledor: Research Support; Insulcloud S.L. C. Abreu: None. E. Fernández-Rubio: Speaker's Bureau; Eli Lilly and Company, Medtronic, Novo Nordisk, Novalab. P. Pujante Alarcón: Speaker's Bureau; Dexcom, Inc., AstraZeneca, Novo Nordisk. S. Azriel: Speaker's Bureau; A. Menarini Diagnostics, Abbott, AstraZeneca, Boehringer-Ingelheim, Dexcom, Inc., Lilly Diabetes, Novartis Pharmaceuticals Corporation, Novo Nordisk Foundation, Sanofi. R. Corcoy: Other Relationship; Lilly Diabetes, Sanofi, Novo Nordisk, Roche Diabetes Care, Abbott Diagnostics, Dexcom, Inc., Menarini. Research Support; Ypsomed AG. Other Relationship; Medtronic. L. Ruiz-Valdepeñas: None.
